

# **CURRICULUM VITAE**

**NAME** Hyun Woo Lee, M.D.

## **EDUCATION**

1991.3.-2001.2 : Ajou University College of Medicine, Suwon, Korea;

Doctor of Medicine

2004.3-2006.2 Ajou University College of Medicine, Graduate

School, Suwon, Korea; Master of Medicine

## **POSTGRADUATE TRAINING**

2001.3-2002.2 Rotating Internship

Ajou University Medical Center, Suwon, Korea

2002.3-2006.2 Junior Medical Resident

Ajou University Medical Center, Suwon, Korea

2006.3-2008.2 Fellowship (Division of Hemato/Oncology)

Ajou University Medical Center, Suwon, Korea

## **ACADEMIC and PROFESSIONAL APPOINTMENTS**

2008.3-2010.2 Instructor

Department of Hematology-Oncology

School of Medicine, Ajou University

Suwon, Korea

2010.2-                   Assistant Professor  
                              Same Institute as above

2012.9-2013.8        Visiting Professor  
                              National Cancer Institute of Canada Clinical Trials Group  
                              Cancer Clinical Trials Division

2016.3-                   Associate Professor  
                              Department of Hematology-Oncology  
                              School of Medicine, Ajou University

## **CERTIFICATES**

2001   Doctor of Medicine, Korea

2006   Specialty in Internal Medicine, Korea

2009   Board of Hematology-Oncology, Korea

## **MEMBERSHIPS in PROFESSIONAL SOCIETIES**

Member of Korean Society of Internal Medicine

Member of Korean Cancer Association

Member of Korean Hematology

Member of Korean Association for Clinical Oncology

Member of Korean Society of Hematopoietic Stem cell transplantation

Member of American Society of Clinical Oncology

Member of Korean Association for the Study of Lung Cancer

Member of International Association for the Study of Lung Cancer (IASLC)

**2012.9. NCIC Clinical Trials Group for GCP training**

**2013.12 Ajou Univ. Medical Center Regional Clinical Trial Center**

**2017.7 Investigator Site Personnel ICH GCP Training Certificate**

1: Heo J, Chun M, Lee HW, Woo JH. Social Media Use for Cancer Education at a Community-Based Cancer Center in South Korea. *J Cancer Educ.* 2016 Dec 12. [Epub ahead of print] PubMed PMID: 27957674.

2: Koh YW, Choi JH, Ahn MS, Choi YW, Lee HW. Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer. *Sci Rep.* 2016 Dec 7;6:38585. doi: 10.1038/srep38585. PubMed PMID: 27924837; PubMed Central PMCID: PMC5141478.

3: Kim SI, Shin JY, Park JS, Jeong S, Jeon YS, Choi MH, Choi HJ, Moon JH, Hwang JC, Yang MJ, Yoo BM, Kim JH, Lee HW, Kwon CI, Lee DH. Vascular enhancement pattern of mass in computed tomography may predict chemo-responsiveness in advanced pancreatic cancer. *Pancreatol.* 2017 Jan - Feb;17(1):103-108. doi: 10.1016/j.pan.2016.10.008. Epub 2016 Oct 19. PubMed PMID: 27780664.

4: An YS, Yoon JK, Lee SJ, Jeong SH, Lee HW. Clinical significance of post-treatment (18)F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma. *Eur Radiol.* 2016 Dec;26(12):4632-4639. Epub 2016 May 18. PubMed PMID: 27193777.

5: Choi YW, Jeon SY, Jeong GS, Lee HW, Jeong SH, Kang SY, Park JS, Choi JH, Koh YW, Han JH, Sheen SS. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. *Am J Clin Oncol.* 2016 Mar 10. [Epub ahead of print] PubMed PMID: 26967328.

6: Lee HW, Noh OK, Oh YT, Choi JH, Chun M, Kim HI, Heo J, Ahn MS, Park SY, Park RW, Yoon D. Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys.* 2016 Mar 1;94(3):621-7. doi: 10.1016/j.ijrobp.2015.11.020. Epub

2015 Nov 18. PubMed PMID: 26867891.

7: Choi YW, Ahn MS, Choi JH, Lee HW, Kang SY, Jeong SH, Park JS, Han JH, Kim JH, Sheen SS. High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy. *Int J Hematol.* 2016 Feb;103(2):210-8. doi: 10.1007/s12185-015-1911-0. Epub 2015 Nov 19. PubMed PMID: 26586460.

8: Kim HJ, Shin SW, Song EK, Lee NR, Kim JS, Ahn JS, Yun HJ, Cho YH, Park KU, Kim SY, Jang JS, Kim SW, Lee HW, Lee SR, Kim YS, Lee SN, Ko YH, Kim HJ, Kang JH. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. *Oncologist.* 2015 Dec;20(12):1440-7. doi: 10.1634/theoncologist.2015-0128. Epub 2015 Oct 28. PubMed PMID: 26512046; PubMed Central PMCID: PMC4679080.

9: Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Park JS. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation. *J Korean Med Sci.* 2015 Oct;30(10):1416-22. doi: 10.3346/jkms.2015.30.10.1416. Epub 2015 Sep 12. PubMed PMID: 26425037; PubMed Central PMCID: PMC4575929.

10: Cho O, Oh YT, Chun M, Noh OK, Lee HW. Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer. *Tumour Biol.* 2016 Jan;37(1):971-8. doi: 10.1007/s13277-015-3888-y. Epub 2015 Aug 12. PubMed PMID: 26264618.

11: Kang SY, Ahn MS, Song GW, Choi YW, Lee HW, Jeong SH, Park JS, Cho YK, Han SU, Sheen SS, Han JH, Choi JH. Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? *Acta Oncol.* 2015;54(8):1231-4. doi: 10.3109/0284186X.2014.1000467. Epub 2015 Jan 22. PubMed PMID: 25608823.

12: Choi YW, Ahn MS, Jeong GS, Lee HW, Jeong SH, Kang SY, Park JS, Choi JH, Lee SY. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer? *Lung Cancer.* 2015 Feb;87(2):155-61. doi: 10.1016/j.lungcan.2014.11.016. Epub 2014 Nov 29. PubMed PMID: 25488862.

13: Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS.

Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. *J Korean Med Sci.* 2014 Nov;29(11):1493-500. doi: 10.3346/jkms.2014.29.11.1493. Epub 2014 Nov 4. PubMed PMID: 25408580; PubMed Central PMCID: PMC4234916.

14: Ahn MS, Kang SY, Lee HW, Jeong SH, Park JS, Lee KJ, Cho YK, Han SU, Lee SY, Lim HY, Choi JH. 5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection. *Onkologie.* 2013;36(7-8):421-6. doi: 10.1159/000349957. Epub 2013 Jun 22. PubMed PMID: 23921761.

15: Ahn S, Park JS, Jeong SH, Lee HW, Park JE, Kim MH, Kim YS, Lee HS, Park TS, You E, Rheem I, Park J, Huh JY, Kang MS, Cho SR. Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea. *Blood Res.* 2013 Mar;48(1):31-4. doi: 10.5045/br.2013.48.1.31. Epub 2013 Mar 25. PubMed PMID: 23589792; PubMed Central PMCID: PMC3625006.

해리슨 내과학 18판 2013.4. 중앙학적 응급상황  
내과학 교과서 역저